因针对聚乙二醇化重组凝血因子Ⅷ的中和抗体导致回收率下降的4例病例报告
2022年12月至2023年5月,挪威奥斯陆血友病综合关怀中心83例成人甲型血友病患者在接受聚乙二醇化重组凝血因子Ⅷ(PEG化rFVIII)试验剂量以转换治疗时,4例(5%)出现回收率下降但无FVIII抑制物,检出抑制性抗PEG/抗PEG化rFVIII抗体,包括持续性和一过性,可解释回收率受损;这些患者首次给药前即存在中和性抗PEG抗体。
要点
- 83例成人甲型血友病患者转换PEG化rFVIII时,4例(5%)出现回收率下降且无FVIII抑制物。
- 4例患者检出抑制性抗PEG/抗PEG化rFVIII抗体,包括持续性和一过性,可解释回收率受损。
- 患者首次PEG化rFVIII给药前已存在中和性抗PEG抗体,且对3种市售PEG化rFVIII产品均检出中和抗体(主要为免疫球蛋白G)。
核心结论
- 具有抑制性抗PEG抗体的患者数量显著,PEG化rFVIII抑制物的存在强调转换FVIII浓缩物时个体化监测对确保治疗安全有效的重要性。
研究设计与样本
- 2022年12月至2023年5月,挪威奥斯陆血友病综合关怀中心83例成人甲型血友病患者接受PEG化rFVIII产品试验剂量以转换治疗。
- 对4例出现回收率下降且无FVIII抑制物的患者,采用不同rFVIII浓缩物作为FVIII来源的变异抑制物试验和酶联免疫吸附试验检测抗PEG抗体。
主要发现
- 4例患者(5%)检出抑制性抗PEG/抗PEG化rFVIII抗体,包括持续性和一过性,可解释回收率受损。
- 这些患者首次PEG化rFVIII给药前已存在中和性抗PEG抗体。
- 检出针对PEG和全部3种市售PEG化rFVIII产品的中和抗体,主要为免疫球蛋白G。
临床怎么用
- 作者强调转换FVIII浓缩物时个体化监测对确保治疗安全有效的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The immunogenicity, safety, and efficacy of recombinant factor VIII (rFVIII) have gained increasing interest after the introduction of extended half-life products with various modifications of the rFVIII molecule, such as covalent attachment of polyethylene glycol (PEG). Anti-PEG antibodies may be associated with a temporary reduction of FVIII recovery, but according to previous studies, they usually disappear after continuous dosing. Anti-PEG antibodies with an inhibitory capacity have never been demonstrated in patients treated with PEGylated rFVIII products. OBJECTIVES: To routinely switch from standard half-life to PEGylated extended half-life rFVIII products in patients with hemophilia A. METHODS: From December 2022 until May 2023, 83 adults with hemophilia A attending Oslo Haemophilia Comprehensive Care Centre received a test dose with a PEGylated rFVIII product to switch treatment. Four patients presented with decreased recovery without the presence of an FVIII inhibitor. Accordingly, we performed a variant inhibitor test utilizing different rFVIII concentrates as a source of FVIII and enzyme-linked immunosorbent assay to search for anti-PEG antibodies. RESULTS: We found inhibitory anti-PEG/anti-PEGylated rFVIII antibodies in 4 patients (5%), both persistent and transient, explaining the impaired recovery. The patients had neutralizing anti-PEG antibodies prior to the first dosing of PEGylated rFVIII. We demonstrated neutralizing antibodies (mainly immunoglobuline G) specific for PEG and all 3 commercially available PEGylated rFVIII products. CONCLUSION: The number of patients with inhibitory anti-PEG antibodies was significant, and the presence of inhibitors against PEGylated rFVIII emphasizes the importance of individual monitoring when switching FVIII concentrates to ensure safety and efficacy of the treatment.
引用
- Hillarp A, Holme PA, Wåland EP, et al. Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII. J Thromb Haemost. 2023. PMID: 37543216. doi:10.1016/j.jtha.2023.07.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。